Descripción de la empresa
Celldex Therapeutics, Inc. operates as a biopharmaceutical entity dedicated to the development of therapeutic antibodies aimed at treating patients suffering from severe inflammatory, allergic, autoimmune, and other complex diseases. The company functions within the broader Healthcare sector, specifically classified under the Biotechnology industry, which typically involves high capital expenditure and long development cycles before potential commercialization. In terms of scale, Celldex Therapeutics maintains a market capitalization of $2.46B, employs 198 individuals, and reported annual revenue of $1.54M over the trailing twelve months. These financial metrics indicate that the company is a small-cap biotechnology firm with a revenue base that is negligible relative to its market valuation, a common characteristic for pre-revenue or early-stage clinical companies where value is derived from intellectual property and pipeline potential rather than current sales volume.
Salud financiera
The financial performance of Celldex Therapeutics is characterized by significant losses relative to its modest revenue stream, with reported revenue of $1.54M, a net income of -$258,756,992, and an EBITDA of -$283,987,008. The substantial disparity between the minimal revenue and the massive negative net income reveals a cost structure dominated by research and development expenses that far exceed current sales, a standard reality for biotechnology firms investing heavily in clinical trials. The company generated a free cash flow of -$125,544,376, indicating a continuous burn rate that consumes cash reserves rather than generating liquidity from operations. Margins reflect this heavy expenditure profile, with a gross margin of 0.0%, an operating margin of -72027.3%, and a profit margin of 0.0%, all signaling that the company is currently operating at a loss and has not yet achieved profitability. Despite these losses, the balance sheet shows a cash position of $518.57M against a debt load of only $2.34M, resulting in a debt-to-equity ratio of 0.44. This disparity suggests a conservative balance sheet structure where cash assets significantly outweigh liabilities, providing ample runway to fund operations without immediate leverage pressure. Liquidity is further evidenced by a current ratio of 10.48, which indicates an exceptionally strong ability to meet short-term obligations with existing assets. Return metrics show a return on equity of -40.6% and a return on assets of -26.1%, revealing that management effectiveness in generating returns is currently negative due to the high costs of development relative to the small equity and asset base.
Evaluación de valoración
Valuation multiples for Celldex Therapeutics present a unique picture given the company's lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -6.62. The negative forward P/E implies that the market is pricing in future earnings expectations that are currently projected to be negative, or that the valuation relies entirely on non-earnings metrics. The price-to-book ratio stands at 3.96, indicating that the market values the company at nearly four times its book value, suggesting a premium assigned to its intangible assets and drug pipeline rather than its tangible assets. Alternative valuation metrics such as a price-to-sales ratio of 1592.12 and an EV/EBITDA of -5.53 highlight that traditional earnings-based valuation is impossible, forcing reliance on revenue multiples that are exceptionally high due to the tiny sales base. Regarding price volatility, the stock traded between a 52-week high of $34.52 and a 52-week low of $14.40. Based on the available data points, the current price sits within this historical range, reflecting the typical fluctuations associated with biotechnology stocks that depend on clinical trial outcomes. The stock exhibits a beta of 1.20, which means its price volatility is 20% higher than the broader market, making it a more aggressive investment relative to大盘指数.
Growth & Income
Celldex Therapeutics experienced a revenue growth of -89.7% year-over-year, while earnings growth is listed as N/A due to the lack of prior comparable earnings data. The absence of positive earnings growth relative to revenue is expected for a company with a gross margin of 0.0% and massive operating losses, as the focus remains on pipeline advancement rather than scaling sales. As a non-dividend payer, the company does not distribute a dividend yield, which is N/A, nor does it maintain a payout ratio, as the value of 0.0% indicates no dividends are paid. This financial profile implies that the company retains all available cash, which is currently $518.57M, to reinvest into its research and development efforts rather than returning capital to shareholders. The overall growth and income profile is defined by negative revenue contraction in the trailing period and a complete absence of dividend income, positioning the company purely as a growth-oriented venture dependent on future clinical successes rather than current financial performance.